Retour
Prix Clarity Pharmaceuticals Ltd (CLRPF)
Graphique du cours de l'action CLRPF
CLRPF Gagner
Clarity Pharmaceuticals Ltd
$2.3
2.22%
$0.04
À la fermeture : Jan 16, 16:00:00 GMT-5
$2.3
0%
$0
Post-Marché: Jan 16, 20:00:00 GMT-5
Earnings FAQ
Comment le bénéfice par action récent de CLRPF se compare-t-il aux attentes ?
Comment les revenus de Clarity Pharmaceuticals Ltd CLRPF se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour Clarity Pharmaceuticals Ltd ?
Quel est le score de qualité des bénéfices pour Clarity Pharmaceuticals Ltd ?
Quand Clarity Pharmaceuticals Ltd publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de Clarity Pharmaceuticals Ltd ?
Clarity Pharmaceuticals Ltd a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$2.25
Prix d'ouverture
$2.3
Plage de la journée
$2.3 - $2.3
Plage de 52 semaines
$0.842 - $3.6
Volume
--
Volume moyen
3.1K
BPA (TTM)
-0.13
Rendement en dividend
--
Capitalisation boursière
$855.6M
Qu’est-ce que CLRPF ?
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing targeted copper theranostics based on its SAR Technology Platform. The company is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.
Fonctionnalités
Stratégies de trading
Ressources
© 2025 Finture Development Limited. All rights reserved